NO20054263L - Fluor- og trifluoralkyl-innholdende heterocykliske sulfonamid inhibitorer av beta amyloid produksjon og derivatar derav - Google Patents

Fluor- og trifluoralkyl-innholdende heterocykliske sulfonamid inhibitorer av beta amyloid produksjon og derivatar derav

Info

Publication number
NO20054263L
NO20054263L NO20054263A NO20054263A NO20054263L NO 20054263 L NO20054263 L NO 20054263L NO 20054263 A NO20054263 A NO 20054263A NO 20054263 A NO20054263 A NO 20054263A NO 20054263 L NO20054263 L NO 20054263L
Authority
NO
Norway
Prior art keywords
optionally substituted
hydrogen
lower alkyl
beta amyloid
trifluoroalkyl
Prior art date
Application number
NO20054263A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054263D0 (no
Inventor
Boyd Lynn Harrison
Derek Cecil Cole
Minsheng Zhang
Anthony Frank Kreft
Scott Christian Mayer
Lynn Resnick
George Diamantidis
Tingzhong Wang
Rocco Galante
Molly Hoke
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20054263D0 publication Critical patent/NO20054263D0/no
Publication of NO20054263L publication Critical patent/NO20054263L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20054263A 2003-03-31 2005-09-15 Fluor- og trifluoralkyl-innholdende heterocykliske sulfonamid inhibitorer av beta amyloid produksjon og derivatar derav NO20054263L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45922803P 2003-03-31 2003-03-31
PCT/US2004/009268 WO2004092155A1 (en) 2003-03-31 2004-03-26 Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof

Publications (2)

Publication Number Publication Date
NO20054263D0 NO20054263D0 (no) 2005-09-15
NO20054263L true NO20054263L (no) 2005-12-14

Family

ID=33299665

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054263A NO20054263L (no) 2003-03-31 2005-09-15 Fluor- og trifluoralkyl-innholdende heterocykliske sulfonamid inhibitorer av beta amyloid produksjon og derivatar derav

Country Status (22)

Country Link
US (3) US7300951B2 (ru)
EP (1) EP1608638A1 (ru)
JP (1) JP2006522126A (ru)
KR (1) KR20060002908A (ru)
CN (2) CN1780829B (ru)
AR (1) AR043940A1 (ru)
AU (1) AU2004230844B2 (ru)
BR (1) BRPI0408962A (ru)
CA (1) CA2517155A1 (ru)
CL (1) CL2004000647A1 (ru)
CO (1) CO5640049A2 (ru)
CR (1) CR7951A (ru)
EC (1) ECSP056128A (ru)
MX (1) MXPA05010368A (ru)
NO (1) NO20054263L (ru)
NZ (1) NZ542468A (ru)
RU (1) RU2342374C2 (ru)
SG (1) SG167669A1 (ru)
TW (1) TWI336698B (ru)
UA (1) UA82093C2 (ru)
WO (1) WO2004092155A1 (ru)
ZA (1) ZA200507896B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1341779T1 (sl) * 2000-12-13 2006-12-31 Wyeth Corp Heterociklicni sulfonamidni inhibitorji produkcije beta amiloida
KR100966705B1 (ko) * 2001-12-20 2010-06-29 브리스톨-마이어스 스큅 컴퍼니 β-아밀로이드 저해제로서의α-(Ν-술폰아미도)아세트아미드 유도체
IL165265A0 (en) * 2002-06-11 2005-12-18 Wyeth Corp Substituted phenylsulfonamide inhibitors of beta amyloid production
CL2004000647A1 (es) * 2003-03-31 2005-02-04 Wyeth Corp Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
JP2007517905A (ja) * 2004-01-16 2007-07-05 ワイス アゾールを含有するベータアミロイド産生のヘテロ環式スルホンアミド阻害剤
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
RU2008129797A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Способы получения сульфонамид-замещенных спиртов и их промежуточных соединений
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
US7550629B2 (en) 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
AU2007243490A1 (en) * 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US20080233132A1 (en) * 2006-11-03 2008-09-25 Miller Stephen D Multiple sclerosis therapy
EP2193117A1 (en) * 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibitors of beta amyloid production
PE20090810A1 (es) * 2007-07-16 2009-07-20 Wyeth Corp Procesos e intermediarios para la preparacion de compuestos de sulfonamida heterociclica
US20090023903A1 (en) * 2007-07-16 2009-01-22 Wyeth Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TW200934482A (en) * 2008-01-11 2009-08-16 Wyeth Corp Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as β -amyloid inhibitors
WO2009137657A1 (en) * 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
EP2334620B1 (en) * 2008-09-05 2018-09-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for enantioseparation of chiral systems with compound formation using two subsequent crystallization steps
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US7977362B2 (en) * 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
WO2011084503A1 (en) * 2009-12-16 2011-07-14 North Carolina Central University Phenoxy thiophene sulfonamides and their use in the treatment of neurodegenerative diseases
US9223209B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing photoresist compositions and methods of use
US9223217B2 (en) * 2010-02-19 2015-12-29 International Business Machines Corporation Sulfonamide-containing topcoat and photoresist additive compositions and methods of use
CA2792613C (en) 2010-03-10 2016-06-28 North Carolina Central University Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
EP2892506B1 (en) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
WO2016069906A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
EP4299062A1 (en) 2022-06-30 2024-01-03 Vilnius University Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
KR920019763A (ko) 1991-04-26 1992-11-19 모리다 가즈라 아졸 화합물, 그의 제조방법 및 용도
GB9110722D0 (en) 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
ZA945719B (en) 1993-08-09 1996-02-01 Lilly Co Eli Identification and use of protease inhibitors
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
KR100490807B1 (ko) 1995-11-28 2005-10-14 세파론, 인코포레이티드 시스테인및세린프로테아제의d-아미노산함유억제제
NZ333825A (en) 1996-07-22 2000-10-27 Monsanto Co Metalloprotease inhibitors particularly MMP-13
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
BR9714358A (pt) 1996-11-22 2000-03-21 Elan Pharm Inc Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
DE19650196A1 (de) 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino(thio)carbonylverbindungen
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
EP1159263A1 (en) 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
EP1172361A4 (en) 1999-04-19 2002-05-08 Shionogi & Co SULFONAMIDE DERIVATIVES HAVING OXADIAZOLE CORES
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
WO2001027091A1 (en) 1999-10-08 2001-04-19 Du Pont Pharmaceuticals Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US7365196B2 (en) 2000-03-20 2008-04-29 Merck Sharp & Dohme Ltd. Sulphonamido-substituted bridged bicycloalkyl derivatives
SI1341779T1 (sl) 2000-12-13 2006-12-31 Wyeth Corp Heterociklicni sulfonamidni inhibitorji produkcije beta amiloida
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
JP4615861B2 (ja) 2001-12-11 2011-01-19 ワイス・エルエルシー キラル的に純粋なα−アミノ酸およびＮ−スルホニルα−アミノ酸の生産
WO2003050063A2 (en) 2001-12-11 2003-06-19 Wyeth PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE β-AMINO-ALCOHOLS
IL165265A0 (en) * 2002-06-11 2005-12-18 Wyeth Corp Substituted phenylsulfonamide inhibitors of beta amyloid production
CL2004000647A1 (es) * 2003-03-31 2005-02-04 Wyeth Corp Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
JP2007517905A (ja) * 2004-01-16 2007-07-05 ワイス アゾールを含有するベータアミロイド産生のヘテロ環式スルホンアミド阻害剤
RU2008129797A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Способы получения сульфонамид-замещенных спиртов и их промежуточных соединений
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
AU2007243490A1 (en) * 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
US20090023903A1 (en) * 2007-07-16 2009-01-22 Wyeth Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides
PE20090810A1 (es) * 2007-07-16 2009-07-20 Wyeth Corp Procesos e intermediarios para la preparacion de compuestos de sulfonamida heterociclica
EP2193117A1 (en) * 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibitors of beta amyloid production

Also Published As

Publication number Publication date
NZ542468A (en) 2009-01-31
RU2005133434A (ru) 2006-07-10
UA82093C2 (ru) 2008-03-11
AU2004230844A1 (en) 2004-10-28
CL2004000647A1 (es) 2005-02-04
CR7951A (es) 2008-10-29
US20090227667A1 (en) 2009-09-10
US20070254929A1 (en) 2007-11-01
RU2342374C2 (ru) 2008-12-27
AR043940A1 (es) 2005-08-17
US7300951B2 (en) 2007-11-27
CN1780829B (zh) 2010-12-29
NO20054263D0 (no) 2005-09-15
ECSP056128A (es) 2006-03-01
AU2004230844B2 (en) 2010-12-09
CN101274926A (zh) 2008-10-01
TWI336698B (en) 2011-02-01
US7858658B2 (en) 2010-12-28
SG167669A1 (en) 2011-01-28
TW200504047A (en) 2005-02-01
BRPI0408962A (pt) 2006-04-04
CO5640049A2 (es) 2006-05-31
KR20060002908A (ko) 2006-01-09
JP2006522126A (ja) 2006-09-28
ZA200507896B (en) 2007-03-28
CA2517155A1 (en) 2004-10-28
WO2004092155A1 (en) 2004-10-28
US20040198778A1 (en) 2004-10-07
MXPA05010368A (es) 2005-11-17
US7547725B2 (en) 2009-06-16
EP1608638A1 (en) 2005-12-28
CN1780829A (zh) 2006-05-31

Similar Documents

Publication Publication Date Title
NO20054263L (no) Fluor- og trifluoralkyl-innholdende heterocykliske sulfonamid inhibitorer av beta amyloid produksjon og derivatar derav
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
ATE398125T1 (de) Chinazolin-derivate als tgf-beta-inhibitoren
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
NO20061793L (no) 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer
NO20061766L (no) 1,1,1-trifluor-4-fenyl-4-metyl-2-(1H-Pyrrolo'2,3-Cl Pyridin-2-ylmetyl)pentan-2-ol derivater og beslektede forbindelser som glukokortikoidligander for behandling av inflammatoriske sykdommer og diabetes
NO20061137L (no) Cyklopropylderivater som NK3-reseptorantagonister
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20064366L (no) Tiazolderivat
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20081945L (no) Forbindelser som har aktivitet som M1 receptor og deres medisinske anvendelse
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
AR004195A1 (es) Nuevos derivados de la 5-0 desosaminil-6-0-metil-eritronolida a, su procedimiento de preparacion, compuestos intermediarios, metodo de aplicacionde los mismos para la preparacion de productos biologicamente activos.
PE20050077A1 (es) Derivados de 4-pirrolidino-fenil-bencil-eter
EA200700103A1 (ru) НОВЫЕ 2-ЗАМЕЩЁННЫЕ D-ГОМО-ЭСТРА-1,3,5(10)-ТРИЕНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1
NO20070564L (no) Kinoliner uten tiazolinonsubstituenter.
NO20062202L (no) Amidometylsubstituerte 2-(4-sulfonylamino)-3-hydroksy-3,4-dihydro-2H-kromen-6-yl-derivater, fremgangsmate og mellomprodukter for deres fremstilling, og legemidler som inneholder disse forbindelsene
NO20064012L (no) Kjemisk prosess
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
NO20064031L (no) Esterderivater av thein og deres terapeutiske anvendelse
DE602004007672D1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application